HER2 and ABCC1 are identified as significant transcriptomic predictors of overall survival in patients treated with T-DXd. A large-scale analysis reveals novel predictors of survival and resistance ...

Researchers have revealed how patients with metastatic breast cancer develop resistance to Enhertu treatment.

Exploratory analysis from Phase 1b/2 breast cancer trial reinforces CD47 as a predictive biomarker for response, as previously observed in the ...

BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard of care therapies in similar patient populationsNo Bria-IMT ...

BriaCell patients treated since 2022 remain alive >18-47 months post enrollment, markedly exceeding benchmarks reported for standard ...

Daiichi Sankyo & AstraZeneca’s Enhertu approved in China as first and only HER2 directed ADC for second-line treatment of patients with HER2 positive metastatic gastric cancer ...

Brazilian researchers have identified previously unknown forms of a protein linked to breast cancer. The discovery ...

EMA validates Enhertu plus pertuzumab type II variation application in EU as first-line treatment of patients with HER2 positive metastatic breast cancer: Tokyo Tuesday, January 2 ...

At the San Antonio Breast Cancer Symposium (SABCS), investigators outlined the rationale and design of the ERADICATE, a first-in-human study evaluating the combination of the oral selective estrogen ...

NEW YORK – Senhwa Biosciences this week said that its investigational agent pidnarulex will be studied in combination with AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) in ...